Design Therapeutics, Inc.

NasdaqGS:DSGN Stock Report

Market Cap: US$184.2m

Design Therapeutics Past Earnings Performance

Past criteria checks 0/6

Design Therapeutics's earnings have been declining at an average annual rate of -49.6%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been declining at an average rate of 150.6% per year.

Key information

-49.6%

Earnings growth rate

-27.9%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-150.6%
Return on equity-24.1%
Net Marginn/a
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Mar 15
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Nov 16
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Jun 06
Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Feb 09
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Oct 25
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Design Therapeutics GAAP EPS of -$0.27 misses by $0.02

Aug 08

We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate

Jul 02
We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Mar 18
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Dec 03
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Aug 18
Here's Why We're Not Too Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Situation

Design Therapeutics expands board of directors

Jun 07

Design Therapeutics EPS misses by $0.24

May 10

Revenue & Expenses Breakdown
Beta

How Design Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:DSGN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-67210
30 Sep 230-72220
30 Jun 230-74210
31 Mar 230-69200
31 Dec 220-63190
30 Sep 220-57180
30 Jun 220-51160
31 Mar 220-43140
31 Dec 210-36110
30 Sep 210-2880
30 Jun 210-1960
31 Mar 210-1340
31 Dec 200-820
31 Dec 191-210

Quality Earnings: DSGN is currently unprofitable.

Growing Profit Margin: DSGN is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: DSGN is unprofitable, and losses have increased over the past 5 years at a rate of 49.6% per year.

Accelerating Growth: Unable to compare DSGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DSGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: DSGN has a negative Return on Equity (-24.08%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.